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Purpose or Objective: To review our outcomes for patients 
in the active inflammatory phase of moderate-to-severe 
Graves’ ophthalmopathy (GO) treated with combined 
systemic pulsed corticosteroids plus irradiation and 
demonstrate the role of magnetic resonance imaging (MRI) as 
a prognostic factor. 
 
Material and Methods: From our database of 35 patients 
treated with radiotherapy for the active inflammatory phase 
of GO in our hospital from January 2005 to December 2013, 5 
patients were excluded from the analysis because they had a 
short follow-up, were not treated with pulsed corticosteroids 
because of liver failure, or had no eye muscle impairment at 
diagnosis. In the remaining 30 patients in the active 
inflammatory phase of moderate-to-severe GO treated with 
combined pulsed corticosteroids plus irradiation, we assessed 
eye muscle impairment using the SPECS system before and 6 
months after the start of treatment. A total dose of 20 Gy in 
10 fractions was delivered to the bilateral retrobulbar 
volume. Intravenous 1 g of corticosteroids daily for 3 
successive days was repeated weekly up to 3 weeks. The 
thickness ratio (TR) of the enlarged eye muscle to the optic 
nerve and the signal intensity ratio (SIR) of the eye muscle to 
the cerebral white matter were evaluated as the mean of 
three cross sections of coronal short-time inversion recovery 
(STIR) sequence MRI to investigate whether these factors 
could predict the reversibility of eye muscle impairment. 
 
Results: This study included 10 men and 20 women with 
median age of 55.5 (range, 37–71) years. The thyroid function 
at the time of irradiation was euthyroid in 26 patients, 
hyperthyroid in 2, and hypothyroid in 2. Median duration of 
eye symptoms from onset to the initiation of radiotherapy 
was 4 months (range, 1.4–22.1 months). Six months after 
radiotherapy, there was a significant improvement in eye 
muscle impairment (p < 0.001); complete regression was 
observed in 10 patients (33%), partial regression in 5 (17%), 
no change in 14 (47%), and progressive disease in 1 (3%). The 
median TR was 4.1 (range, 0.4–16.4), and the median SIR was 
2.45 (range, 1.7–4.1). There was a trend toward greater, but 
not significant, improvement in patients with a low TR (<4.2) 
or high SIR (>2.5) before treatment. 
 
Conclusion: Orbital irradiation combined with pulsed 
corticosteroids was an effective treatment for the active 
inflammatory phase of moderate-to-severe GO, especially in 
patients with a low TR or high SIR on MRI before treatment. A 
low TR or high SIR may predict the treatment outcome. 
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Purpose or Objective: The radiotherapy treatment can 
produce a possible new second primary cancer, but 
metachronous malignancies can also appear without any 
relationship with radiotherapy treatment. We have studied 
the risk of developing a potential radiotherapy induced 
second cancer.  
 
Material and Methods: We analyse the new second cancers 
after a radiotherapy treatment for a primary cancer in a 
population-based study in a province of Spain from 2000 to 
2011.  
 
Results: The number of patients (pts) with cancer treated 
with radiotherapy during this period was 14131, 2989 were 
breast cancer, 2197 were prostate cancer and 1220 pts were 
rectal cancer. Three hundred and thirteen (2.2%) patients 
developed a second cancer after a primary cancer treated 
with radiotherapy. In relation to the primary cancer, the 
most frequent were prostate cancer (70 pts, 22.4%), the 
second breast cancer (43 pts, 13.7%), the third colorectal 
cancer (40 pts, 12.8%), the fourth skin cancer (36 pts, 11.5%) 
and the fifth larynx (24 pts). The others were bladder (20 
pts), oropharynx (7), endometrial cancer (6), etc. The most 
frequent of second cancer location was lung cancer (63 
cases, 20.1%), the second colorectal cancer (43 cases, 
13.7%), the third larynx and oral cavity and pharynx (40 
cases, 12.8%), breast (34, 10.9%), prostate (28, 8.9%), 
bladder (19.6%). The location more frequent after a prostate 
cancer irradiation is lung (20 pts) and colorectal (17 pts, 9 
rectal and 8 colon) and bladder (8). The location more 
frequent in after a breast cancer irradiation is another breast 
cancer (21 pts). Colorectal 40 pts: 9 second colorectal, 8 lung 
cancer. Non-melanoma skin cancer 36 pts: 8 second non-
melanoma skin cancer, 6 rectal cancer and 4 lung cancer. 
Larynx 24 pts: 7 lung cancer, 4 prostate cancers.  
 
Conclusion: The percentage of pts treated with radiotherapy 
who developed a second cancer after 11 years is 2.2% in our 
series. It’s difficult to know the real probability for 
developing a second cancer associated with radiotherapy. 
The higher percentage of primary tumour with second cancer 
was rectal cancer (40/1220, 3.27%), the second was prostate 
cancer (70/2197, 3.18%), the third was breast cancer 
43/2989, 1.43%). We’ll present the results about the location 
of second cancer, the time between the primary and the 
second cancer, and some characteristics about the 
radiotherapy treatment (total dose and other dosimetric 
characteristics).  
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Purpose or Objective: For many years Edinburgh Cancer 
Centre's radiotherapy skin care policy recommended aqueous 
cream and, if required, 1% hydrocortisone. However, it was 
increasingly appreciated that better alternatives existed so in 
2015, a review of the literature was performed, and a new 
skincare policy developed based on:  
1) Low Risk (treatment only if symptoms),  
2) Medium Risk (Diprobase moisturising cream),  
3) High Risk of developing radiation dermatitis (Diprobase & 
betamethasone valerate 0.1% applied once daily from 1st 
fraction till 14 days after treatment). The High Risk group 
included patients with breast, head and neck, anal, or pelvic 
cancers when body mass index >35 kg/m2.  
As concerns were raised about the increased cost and 
potential extent of the clinical benefit, a prospective audit 
was conducted. 
 
Material and Methods: For one month prior to the change of 
policy (cohort 1, C1), all patients in High Risk group 
completed a questionnaire at the end of their course of 
radiotherapy, scoring (categorical 0-10) their skin reaction 
for redness, itch, discomfort and pain, and asking what 
creams and analgesia they were using, and if the reaction 
disturbed their sleep. The audit was repeated for cohort 2 
(C2) four months after the policy changed and the two groups 
compared using Chi-squared and ANOVA. 
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Results: C1 = 109 patients (84 with breast cancer, 13 H&N, 
12 pelvis), C2= 104 (87B, 12H&N, 5P). In C1 27% used a cream 
and in C2 96% used a cream (p<0.001). In C2 88/104 complied 
with policy using the prescribed betamethasone.  
Compared to C1, for C2 the mean score was lower for itch 
(1.3 (0.8-1.8) v 2.8 (2.2-3.4) p<0.001) and discomfort (2.2 
(1.7-2.7) v 3.1 (2.6-3.7) (p=0.021), and when betamethasone 
was used (comparing the 88 from C2 with 125 from C1 or C2) 
the mean score was lower for itch (0.9 (0.5-1.4) v 2.9 (2.3-
3.4) p<0.001), discomfort (2.0 (1.4-2.5) v 3.2(2.6-3.7) 
p<0.003), and for pain (1.4 (0.9-1.9) v 2.2 (1.7-2.7) p=0.03).  
With the use of betamethasone, the frequency of a score of 
>5 was lower for redness (15% with v 34% without) p=0.002), 
itch (7% v 25%, p =0.001), discomfort (9% v 22%, p=0.015), but 
not for pain (9% v 14%, p=0.29). However, sleep disturbance 
was less common (7% v 21%, p=0.006), as was the use of 
analgesia (7% v 19%, p=0.015). 
 
Conclusion: The introduction of routine use of prophylactic 
betamethasone cream for patients with a high risk of 
radiation skin reaction resulted in a significant reduction in 
redness, itch, discomfort, sleep disturbance, and on use of 
analgesia 
 
EP-1469  
Survey on the use of complementary and alternative 
medicine in a German radiooncology department 
S. Lettner
1Technische Universität München TUM, Department of 
Radiation Oncology, München, Germany 
1, K.A. Kessel1,2, S.E. Combs1,2 
2Institute of Innovative Radiotherapy iRT, Helmholtz 
Zentrum München, München, Germany 
 
Purpose or Objective: The use of complementary and 
alternative medicine (CAM) continuously gains importance, 
even though objective data are mostly missing – also in 
radiation oncology. However, in previous trials methods such 
as acupuncture showed significant advantages compared to 
standard therapies. Hence, the aim of this study is to 
evaluate the most frequently used methods, their 
significance and potential effect during radiotherapy (RT), as 
well as the general acceptance amongst cancer patients. 
 
Material and Methods: A detailed questionnaire was 
developed consisting of 18 questions based on the categorical 
classification released by the National Centre for 
Complementary and Alternative Medicine (NCCAM). From 
January to September 2015, the survey was conducted with 
all patients undergoing RT at the department of Radiation 
Oncology, Technische Universität München (TUM), Klinikum 
rechts der Isar, Munich. Participation was voluntary and 
pseudonymous. 
 
Results: Of 571 patients, 289 answered the questionnaire 
(50.6%), with 44.6% females and 38.4% males participating in 
the study, and a mean age of 60 years. Of these, 66.1% 
(191/289) received RT only, 20.4% (59/289) had a combined 
radio-chemotherapy (RCT). Of all participants, 25.9% 
(75/289) used CAM parallel to RT. Before RT, a total of 40.8% 
(118/289) had already used complementary medicine. The 
current most frequently applied methods were vitamins, 
dietary supplements, homeopathy and physical therapy, 
whereas in the past before RT also acupuncture and 
osteopathy had been regularly used. The majority (72.6%, 
210/289) declined the use of any complementary treatment. 
Of these 210 patients, 73.3% (154/210) stated that CAM 
treatment was not offered to them. Only 20.4% (59/289) of 
all participants had discussed adding complementary 
treatments to their current therapy with their consulting 
physician. The most common reasons for CAM use were 
intended by the patients to improve the immune system 
(47%, 136/289), to reduce side effects (43.2%, 125/289), and 
to not miss an opportunity (37.3%, 108/289). Assuming their 
health insurance would not compensate the costs for CAM 
during RT, 52.5% (152/289) of the patients would pay for 
their treatment. A treatment integrated in the individual 
therapy concept, such as regular acupuncture, would be used 
by 62.9% (182/289) of RT patients. In order to gain more 
information about the changes in attitude towards 
complementary medicine, we also handed out the 
questionnaire a second time after RT during the first follow-
up visit (n=10). This is an ongoing part of the evaluation. 
However, it becomes apparent that in retrospect the use of 
CAM increased.  
 
Conclusion: In comparison to other studies, usage of CAM 
parallel to RT is considered to be low. The acceptance 
amongst patients is present, however more information, in 
terms of personal consultations with physicians, brochures or 
online information, could encourage a holistic therapy. 
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Purpose or Objective: On the basis of successful 
intralesional steroid injection for dermatologic scars 
treatment such as keloids and burn scars, we planned to 
evaluate intralesional triamcinolone acetonide injection in 
treatment of RIF as there is no data available for its use for 
this indication 
 
Material and Methods: 30 patients with RIF of different sites 
(19 cases breast, 4 cases neck, 3 back, 2 face and 2 lower 
limbs) at least 6 months after end of radiation were included 
in our study. They were treated by intralesional 
Triamcinolone acetonide injection. Injections were carried 
out by dermojet at 1 cm interval. Injections were repeated 
every 2 weeks for 3months. Assessment was done according 
to RTOG grading before treatment and repeated during and 3 
months after end of treatment. 
 
Results: We documented over all response rates of 80%, 
marked and complete improvement of RIF 43.33%, 30% 
showed one grade improvement, 6.67% had two grades 
improvement, while 20% of patients didn't respond (P-value 
<0.001). Pain score was significantly improved (p value 
<0.001), 44% of the included patients had complete 
improvement of pain, 36% had mild residual pain and 20% of 
patients expressed moderate residual pain. No significant 
adverse events were observed. The results were significantly 
better with younger age group (P-value=0.021), smaller BMI 
(p-value=0.007), patients who received lower radiation doses 
(P value =0.03), smaller number of radiotherapy treatment 
sessions (P-value=0.05), smaller radiation field sizes (P 
value=0.001), and patients with shorter duration of RIF (P 
value <0.001). 
 
Conclusion: Intralesional triamcinolone acetonide injection 
can be considered as an effective in treatment of RIF. It can 
be considered as a promising effective, safe, less costly 
therapeutic option in treatment of RIF. To the best of our 
knowledge, no previous data are available about the use of 
intralesional injection of triamcinolone acetonide for 
treatment of RIF. 
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Purpose or Objective: The only treatment option for 
Ledderhose disease seems radiotherapy as surgery is 
associated with a high chance of recurrence and morbidity. 
